Abstract
PS-341, a potent and selective proteasome inhibitor, is the prototype for a new class of therapeutics that targets the ubiquitin-proteasome pathway. It is active as a single agent and potentiates chemotherapy and radiation in pre-clinical models. Early phase clinical studies have demonstrated tolerability and activity in multiple myeloma, lymphoma, prostate cancer and lung cancer. By its mechanism of inhibiting protein degradation, PS-341 targets a wide-range of pathways that are relevant to tumor progression and therapy resistance, and can directly modulate expression of cyclins, p27Kip1, p53, NF-κB, Bcl-2 and Bax. PS-341 is currently in phase I/II clinical development in lung cancer. This paper will review the pre-clinical and clinical experience with PS-341 as it relates to lung cancer.
Original language | English (US) |
---|---|
Journal | Lung Cancer |
Volume | 41 |
Issue number | SUPPL. 1 |
DOIs | |
State | Published - Aug 1 2003 |
Keywords
- Lung cancer
- Proteasome inhibitor
- PS-341
ASJC Scopus subject areas
- Oncology